Schlackow I, et al. - Researchers assessed quality-adjusted life years (QALYs) and healthcare costs related to treatment with statins and ezetimibe for lowering lipid in patients with non-dialysis chronic kidney disease (CKD) in the United States and the United Kingdom by using the Study of Heart and Renal Protection (SHARP)CKD-CVD policy model. Cost-effectiveness was defined as net costs below $100,000/QALY (US) or £20,000/QALY (UK). In non-dialysis patients with stages 3B to 5 CKD, an increase in life expectancy by 0.23 to 0.31 QALYs was achieved with atorvastatin 40 mg ($0.103/day as of January 2019), at a net cost of $20,300 to $78,200/QALYs in the United States. An additional increase in life expectancy by 0.05 to 0.07 QALYs was noted with the addition of ezetimibe ($0.203/day) at a net cost of $43,600 to $91,500/QALY. Findings highlighted the cost-effectiveness of statin/ezetimibe combination therapy for attenuating cardiovascular disease risk in patients with non-dialysis-dependent CKD.